Sanofi is committed to medical innovation, disease prevention, patient support and improving access to health care. With those commitments in mind, the Sanofi Innovation Awards program (Sanofi iAwards) intends to create an early-stage research culture that can quickly translate innovative academic research and findings into clinical testing of new pharmaceutical and therapies that could have significant impact on patients.
"This is a valuable opportunity for UT System researchers across its campuses and health institutions to secure funding for projects that may lead to important new discoveries," said Patricia Hurn, Ph.D., UT System's vice chancellor for research and innovation.
Funded up to $2.4 million a year for the next three years collectively with all participating institutions, the program will support innovative collaborative research to accelerate the R&D process and address patient needs. Sanofi and its participating academic institutions will create a joint scientific steering committee responsible for reviewing and providing input on research proposals from the UT System and other research institutions such as Johns Hopkins University, University of Pennsylvania, Weill Cornell Medical College, Columbia University, Brigham and Women's Hospital and Massachusetts General Hospital.
The UT System is the only university system in the program, and each of its academic campuses and health institutions can participate in the program. David Russell, Ph.D., vice provost and dean of basic research at UT Southwestern Medical Center, will serve as the UT System representative on the joint scientific steering committee.
The UT System's participation in the Sanofi iAwards program was an outcome of the UT System's Texas FreshAIR (Academia Industry Roundtable) initiative. Beena Koshy, Ph.D., UT System's assistant vice chancellor for innovation & industry partnerships who leads the Texas FreshAIR initiative, said the Sanofi iAwards program will help accelerate more commercial collaborations for UT System researchers.